MX367260B - Tabletas de rucaparib de dosificación elevada. - Google Patents
Tabletas de rucaparib de dosificación elevada.Info
- Publication number
- MX367260B MX367260B MX2017001540A MX2017001540A MX367260B MX 367260 B MX367260 B MX 367260B MX 2017001540 A MX2017001540 A MX 2017001540A MX 2017001540 A MX2017001540 A MX 2017001540A MX 367260 B MX367260 B MX 367260B
- Authority
- MX
- Mexico
- Prior art keywords
- rucaparib
- high dosage
- tablet
- dosage strength
- strength tablets
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040849P | 2014-08-22 | 2014-08-22 | |
| US201562101739P | 2015-01-09 | 2015-01-09 | |
| PCT/US2015/045522 WO2016028689A1 (en) | 2014-08-22 | 2015-08-17 | High dosage strength tablets of rucaparib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017001540A MX2017001540A (es) | 2017-05-11 |
| MX367260B true MX367260B (es) | 2019-08-12 |
Family
ID=55347324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001540A MX367260B (es) | 2014-08-22 | 2015-08-17 | Tabletas de rucaparib de dosificación elevada. |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9987285B2 (enExample) |
| EP (1) | EP3182975B1 (enExample) |
| JP (3) | JP6574477B2 (enExample) |
| KR (2) | KR20170043597A (enExample) |
| CN (2) | CN113209033A (enExample) |
| AU (2) | AU2015305696B2 (enExample) |
| BR (1) | BR112017000865A2 (enExample) |
| CA (1) | CA2955495C (enExample) |
| DK (1) | DK3182975T3 (enExample) |
| ES (1) | ES3048688T3 (enExample) |
| FI (1) | FI3182975T3 (enExample) |
| HR (1) | HRP20251484T1 (enExample) |
| IL (1) | IL249946B (enExample) |
| LT (1) | LT3182975T (enExample) |
| MX (1) | MX367260B (enExample) |
| NZ (1) | NZ728392A (enExample) |
| PT (1) | PT3182975T (enExample) |
| RS (1) | RS67356B1 (enExample) |
| RU (1) | RU2705156C2 (enExample) |
| SG (1) | SG11201700265VA (enExample) |
| SI (1) | SI3182975T1 (enExample) |
| WO (1) | WO2016028689A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383378B (es) | 2014-02-05 | 2025-03-13 | Merck Sharp & Dohme Llc | Formulación de tableta para compuestos activos de péptido relacionado con el gen de calcitonina. |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| ES3048688T3 (en) | 2014-08-22 | 2025-12-11 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
| CN106008530B (zh) * | 2016-07-24 | 2018-06-26 | 石家庄久正生物科技有限公司 | 一种抗卵巢癌药物Rucaparib关键中间体的制备方法 |
| CN108201534A (zh) * | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种瑞卡帕布口服缓控释药物组合物及其用途 |
| US10875870B2 (en) | 2017-01-24 | 2020-12-29 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib and of rucaparib salts |
| CN110944638A (zh) | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| JP7269227B2 (ja) | 2017-09-26 | 2023-05-08 | テサロ， インコーポレイテッド | ニラパリブ処方物 |
| WO2019130229A1 (en) | 2017-12-28 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing rucaparib |
| BR112020013672A2 (pt) | 2018-01-05 | 2020-12-01 | Cybrexa 1, Inc. | compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US12090148B2 (en) | 2020-07-29 | 2024-09-17 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CN109111454A (zh) * | 2018-08-01 | 2019-01-01 | 宁波金未生物科技有限公司 | 一种瑞卡帕布s-樟脑磺酸盐 |
| CN108853030B (zh) * | 2018-09-26 | 2021-10-01 | 上海朝晖药业有限公司 | 一种治疗恶性肿瘤的药物制剂及其制备方法 |
| CN111542527A (zh) * | 2018-12-06 | 2020-08-14 | 上海诚妙医药科技有限公司 | 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途 |
| BR112022000337A2 (pt) | 2019-07-10 | 2022-04-12 | Cybrexa 2 Inc | Conjugados de peptídeos de citotoxinas como terapêuticos |
| AU2020311925A1 (en) | 2019-07-10 | 2022-02-03 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| WO2021220120A1 (en) | 2020-04-28 | 2021-11-04 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| HRP20251324T1 (hr) | 2020-07-14 | 2025-12-05 | Assia Chemical Industries Ltd. | Oblici soli rukapariba u krutom stanju |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| WO2022140537A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CA3214298A1 (en) | 2021-04-08 | 2022-10-13 | Swaroop Kumar Venkata Satya VAKKALANKA | Inhibitors of poly(adp-ribose) polymerase |
| AU2022353124A1 (en) | 2021-09-27 | 2024-04-11 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
| EP4429636A1 (en) * | 2021-11-10 | 2024-09-18 | Crititech, Inc. | Rucaparib particles and uses thereof |
| EP4463232A1 (en) | 2022-01-11 | 2024-11-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2360003C (en) | 1999-01-11 | 2012-07-10 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerases |
| WO2004087713A1 (en) | 2003-03-31 | 2004-10-14 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| ES2339663T3 (es) | 2003-07-25 | 2010-05-24 | Cancer Research Technology Limited | Inhibidores de parp triciclicos. |
| JP4966858B2 (ja) | 2004-09-22 | 2012-07-04 | ファイザー・インク | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害薬の製造方法 |
| ES2382950T3 (es) | 2004-09-22 | 2012-06-14 | Pfizer, Inc. | Formas polimorfas de la sal de fosfato de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-acepin[5,4,3-cd]indol-6-ona |
| NZ553295A (en) | 2004-09-22 | 2010-04-30 | Pfizer | Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor |
| CA2720744A1 (en) * | 2008-04-09 | 2009-10-15 | Lek Pharmaceuticals D.D. | Granulation of active pharmaceutical ingredients |
| PL2534153T5 (pl) | 2010-02-12 | 2024-11-18 | Pfizer Inc. | Sole i polimorfy 8-fluoro-2-{4-[(metyloamino}metylo]fenylo}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-onu |
| AU2013243291B2 (en) | 2012-04-05 | 2018-02-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
| ES3048688T3 (en) | 2014-08-22 | 2025-12-11 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
-
2015
- 2015-08-17 ES ES15833096T patent/ES3048688T3/es active Active
- 2015-08-17 DK DK15833096.9T patent/DK3182975T3/da active
- 2015-08-17 KR KR1020177007284A patent/KR20170043597A/ko not_active Ceased
- 2015-08-17 HR HRP20251484TT patent/HRP20251484T1/hr unknown
- 2015-08-17 SI SI201532081T patent/SI3182975T1/sl unknown
- 2015-08-17 MX MX2017001540A patent/MX367260B/es active IP Right Grant
- 2015-08-17 CN CN202110458329.2A patent/CN113209033A/zh active Pending
- 2015-08-17 CN CN201580042815.9A patent/CN106794185A/zh active Pending
- 2015-08-17 BR BR112017000865A patent/BR112017000865A2/pt not_active Application Discontinuation
- 2015-08-17 FI FIEP15833096.9T patent/FI3182975T3/fi active
- 2015-08-17 NZ NZ728392A patent/NZ728392A/en unknown
- 2015-08-17 LT LTEPPCT/US2015/045522T patent/LT3182975T/lt unknown
- 2015-08-17 RS RS20251082A patent/RS67356B1/sr unknown
- 2015-08-17 AU AU2015305696A patent/AU2015305696B2/en active Active
- 2015-08-17 CA CA2955495A patent/CA2955495C/en active Active
- 2015-08-17 KR KR1020237020594A patent/KR102803917B1/ko active Active
- 2015-08-17 WO PCT/US2015/045522 patent/WO2016028689A1/en not_active Ceased
- 2015-08-17 EP EP15833096.9A patent/EP3182975B1/en active Active
- 2015-08-17 PT PT158330969T patent/PT3182975T/pt unknown
- 2015-08-17 US US14/828,065 patent/US9987285B2/en active Active
- 2015-08-17 RU RU2017109139A patent/RU2705156C2/ru active
- 2015-08-17 SG SG11201700265VA patent/SG11201700265VA/en unknown
- 2015-08-17 JP JP2017510539A patent/JP6574477B2/ja active Active
-
2017
- 2017-01-05 IL IL249946A patent/IL249946B/en active IP Right Grant
-
2018
- 2018-03-14 US US15/920,643 patent/US10130636B2/en active Active
- 2018-10-08 US US16/154,038 patent/US20190099430A1/en not_active Abandoned
-
2019
- 2019-08-15 JP JP2019149084A patent/JP6797980B2/ja active Active
- 2019-11-29 AU AU2019272064A patent/AU2019272064B2/en active Active
-
2020
- 2020-11-18 JP JP2020191356A patent/JP7127101B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017001540A (es) | Tabletas de rucaparib de dosificacion elevada. | |
| HUS2200054I1 (hu) | 2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszerelése | |
| PH12017500408B1 (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
| PH12017500802A1 (en) | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof | |
| CL2016002310A1 (es) | Nuevos compuestos bicíclicos. | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| SI3152212T1 (sl) | Radioaktivno označeni derivati 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)-pirazolo (1,5-A)pirimidin-3- karboksamidne spojine, koristni kot inhibitor kinaze ATR, priprava navedene spojine in njene različne trdne oblike | |
| IL248546B (en) | A multi-fluorinated compound as an inhibitor of proton tyrosine kinase | |
| SI3077397T1 (sl) | 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati | |
| WO2017075629A3 (en) | Wee 1 kinase inhibitors and methods of making and using the same | |
| UA111804C2 (uk) | ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK) | |
| SI3227297T1 (sl) | 4,6-substituirani-pirazolo(1,5-A)pirazini kot inhibitorji Janus kinaze | |
| CL2013002063A1 (es) | Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune. | |
| PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
| CL2016000496A1 (es) | Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias. | |
| IL250022B (en) | 1-(pyrimidin-2-yl)-6-(heterocyclyl-carbonyl)-(indoline/2,3-dihydroazaindole) derivatives, process for their preparation and pharmaceutical compositions comprising them | |
| WO2016073771A3 (en) | Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors | |
| GEAP201814408A (en) | Quinolizinone derivatives as pi3k inhibitors | |
| SI3596080T1 (sl) | Farmakološko aktivni aliciklični-substituirani pirazolo-(1,5-a)pirimidinski derivati | |
| PL3102187T3 (pl) | Stabilne kompozycje farmaceutyczne zawierające sitagliptynę w postaci tabletek o natychmiastowym uwalnianiu | |
| MX2017008931A (es) | Formulaciones farmaceuticas de xantina o derivados de xantina. | |
| PH12016502540A1 (en) | Pharmaceutical dosage forms | |
| HK1236035A1 (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | |
| HK1236034A1 (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |